MORE►
ophthalmology
Bedford-based Nanoscope Instruments Inc.’s new patent covers an apparatus and method for measuring the functional vision of patients with low vision. [Illustration: Sources, USPTO Patent No. 12702291-B2; DI Studio]
Patented: Nanoscope Instruments’ Low-Vision Function Test and 134 More Inventions Across North Texas
by Dave Head | Sep 2, 2026
Dallas-Fort Worth ranked No. 9 among 250 U.S. metros in patent production for the week of Aug. 11, with 135 patents granted to inventors and companies across the region.
by Lance Murray |
Apr 26, 2024
Dallas-based Nanoscope said Dr. Allen C. Ho will help define the strategy of developing its gene mutation-agnostic therapies. Ho is attending surgeon and director of retina research at Wills Eye Hospital and co-director of the Wills Eye Hospital Retina Service.
MORE►
by Lance Murray |
Oct 27, 2023
Najam Sharif, Ph.D., DSc, has been appointed as vice president of global research and development by Dallas-based Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases.
Sharif is a veteran in drug/device discovery and development, the company said.
“We are delighted to welcome Naj to the Nanoscope team,” Sulagna Bhattacharya, co-founder and CEO of Nanoscope, said in a statement....
MORE►
by Lance Murray |
Sep 22, 2023
Samuel Barone, M.D., is a former Federal Drug Administration official and leader in the pharmaceutical space.
MORE►
Marketing image for one of Eyevance Pharmaceuticals' products, Flarex. [eyevance.com]
Fort Worth Ophthalmic Biotech Eyevance Exits to Japanese Firm for $225M
by Alex Edwards | Sep 17, 2020
Eyevance Pharmaceuticals, which develops and commercializes ophthalmic products, has been purchased for $225 million by Santen, a Japanese leader in ophthalmology. Eyevance will join Santen's U.S. organization.
MORE►
by Lance Murray |
Jan 8, 2020
The startup plans to use the funding to continue developing its technology and to position it as an innovator in ophthalmology. Eyevensys’ tech is a gene therapy platform to deliver ocular drugs via an electrotransfection system to the ciliary muscle of the eye.
MORE►
by Lance Murray |
May 10, 2019
You’ll also find out why the Association for Research in Vision and Ophthalmology has honored a professor at the UNT Health Science Center in Fort Worth in this roundup of research and development activity in North Texas.
MORE►
